Results 61 to 70 of about 416,036 (340)

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers. [PDF]

, 2019
For long, the treatment of locoregionally advanced laryngeal and hypopharyngeal squamous cell cancers (SCC) consisted of either total laryngectomy (TL) or definitive radiotherapy (RT).
Argiris, Athanassios, Lefebvre, Jean Louis   +1 more
core   +2 more sources

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice

BMC Nephrology
Background Pemetrexed is combined with cisplatin to treat cancer. Whether pemetrexed-cisplatin combination chemotherapy exacerbates cisplatin nephrotoxicity is unclear.
Samson A. Iwhiwhu, Ravi Kumar, Abdul H. Khan, Jeremiah M. Afolabi, Jada D. Williams, Julia E. de la Cruz, Adebowale Adebiyi   +6 more
doaj   +1 more source

miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. [PDF]

, 2015
MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC).
Cao, Yan, Huang, Pu-wen, Lou, Jian-fang, Pan, Shi-yang, Rao, Jian-yu, Shi, Xin-hui, Sun, Rui-hong, Wang, Fang, Wang, Hong, Wang, Peng, Xie, Er-fu, Xu, Jian, Xu, Ting   +12 more
core   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

Molecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho   +10 more
wiley   +1 more source

Synergistic Effect of Anethole and Platinum Drug Cisplatin against Oral Cancer Cell Growth and Migration by Inhibiting MAPKase, Beta-Catenin, and NF-κB Pathways

Pharmaceuticals, 2023
Cisplatin is a common drug used to treat patients with oral squamous cell carcinoma. However, cisplatin-induced chemoresistance poses a major challenge to its clinical application.
Abdelhabib Semlali, Ikram Ajala, Sarra Beji, Mohammed Mousa Al-Zharani, Mahmoud Rouabhia   +4 more
doaj   +1 more source

Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma [PDF]

New England Journal of Medicine, 2009
Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).Children with standard-risk hepatoblastoma who were younger than 16 years of age were eligible for inclusion ...
PERILONGO, GIORGIO, MAIBACH R, SHAFFORD E, BRUGIERES L, BROCK P, MORLAND B, DE CAMARGO B, ZSIROS J, ROEBUCK D, ZIMMERMANN A, ARONSON D, CHILDS M, WIDING E, LAITHIER V, PLASCHKES J, PRITCHARD J, SCOPINARO M, MACKINLAY G, CZAUDERNA P.   +18 more
openaire   +5 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer

Frontiers in Pharmacology, 2017
Cisplatin (DDP) is currently one of the most commonly used chemotherapeutic drugs for treating ovarian and lung cancer. However, resistance to cisplatin is common and it often leads to therapy failure.
Wujian Zheng, Qi Feng, Jiao Liu, Yanke Guo, Lvfen Gao, Ruiman Li, Meng Xu, Guizhen Yan, Zhinan Yin, Shuai Zhang, Shuangping Liu, Changliang Shan   +11 more
doaj   +1 more source